Ophthalmology Clinical Conference - Retina

Friday, April 14, 2023, 8:00 AM - 12:00 PM, Braley Auditorium (01136 PFP), Iowa City, IA

Describe up-to-date ocular treatments and therapies and how those correlate to patient care. More effectively describe, diagnose and treat common and rare ocular diseases. Recall research being conducted in our Department and the Institute of Vision Research.

AMA PRA Category 1 Credits™ (4.00 hours), Non-Physician Attendance (4.00 hours)

1. To determine a role for the intestinal microbiome in ocular inflammatory disease.
2. To better define the pathogenesis of noninfectious uveitis
3. To improve understanding of the indications and complications of local and systemic treatment in uveitis

Registration Options: 

• UIHC Faculty and Staff - $0.00
• UIHC Residents, Fellows, Students - $0.00
• External Provider (Iowa Eye Association Member) - $0.00
• External Provider (non-Iowa Eye Association Member) - $70.00

 Not sure if you're an Iowa Eye Association Member?  Want to check and/or join?  Click here - my.cheddarup.com/c/2023-iowa-eye-association-dues

Cancellation Policy

Cancellation fee: $25

All but $25.00 of the fee is refundable if inability to attend is made known on or before April 4, 2023.  No refunds for cancellations made after April 4, 2023, or no shows.  

In support of improving patient care, the University of Iowa Roy J. and Lucille A. Carver College of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Mitigation of Relevant Financial Relationships

University of Iowa Roy J. and Lucille A. Carver College of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships have been mitigated prior to the commencement of the activity.